Game changer for ophthalmic diseases

Eyevensys is pioneering mini-invasive electroporation to express therapeutic proteins in situ to treat major ophthalmic diseases. To download the full article, please sign in.

Go to the profile of Eyevensys
Nov 05, 2015
Page of
Go to the profile of Eyevensys


Eyevensys is a privately owned company based in Paris. Eyevensys was founded in December 2008 on the basis of research work conducted through the INSERM lab UMRS872 directed by Professor Francine Behar-Cohen, then, Professor of medicine at Paris Descartes University, head of ophthalmology at Hotel Dieu and currently Chairman of the Hopital Jules Gonin of Lausanne, Switzerland. Eyevensys’ mission is to improve patient outcome through the development of innovative therapeutic solutions fulfilling critical unmet needs with current therapies in ophtalmology, with the aim to improve short and long term outcome, compliance and tolerability.

Comments are disabled